** ASX-listed shares of Aroa Biosurgery rise as much as 15.4% to A$0.6, their highest since Aug. 12
** NZ's Medical products maker expects to be operating cash flow positive in the second half of FY25
** Co says FY25 normalised EBITDA guidance maintained at NZ$2 mln ($1.21 mln) to NZ$6 mln
** Says, FY25 revenue guidance maintained between NZ$80 mln and NZ$87 mln
** ARX to release financial results for H1 FY25 on Nov. 26
** Stock down 30.7% YTD
($1 = 1.6543 New Zealand dollars)
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。